Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1277 views | HTML 1913 views | ?
Shimin Wang1, Zhi’an Li2 and Guoming Hu3
1Department of Nephrology, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China
2Department of Surgical Oncology, Shaoxing Second Hospital, 312000, Zhejiang, China
3Department of General Surgery, Breast and Thyroid Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China
Guoming Hu, email: [email protected]
Keywords: intratumoral IL-17A overexpression, immunohistochemistry, worse outcome, solid tumor, meta-analysis
Received: February 06, 2017 Accepted: May 20, 2017 Published: June 29, 2017
IL-17A is an important proinflammatory cytokine which is frequently elevated in tumor microenvironment. However, the role of intratumoral IL-17A in solid tumors remains controversial. Herein, we conducted a meta-analysis to assess the prognostic impact of intratumoral IL-17A in patients with solid tumor. PubMed and EBSCO were searched to identify the studies evaluating the associations between intratumoral IL-17A measured by immunohistochemistry (IHC) and overall survival (OS) and disease-free survival (DFS) in solid tumors. A total of 2972 patients with solid tumor from 21 published studies were incorporated into this meta-analysis. We found that high level of intratumoral IL-17A was significantly associated with worse 3-year, 5-year OS and 1-year, 3-year DFS, but not with 1-year OS or 5-year DFS in solid tumors. In addition, in stratified analyses by cancer types, IL-17A overexpression was significantly associated with worse OS in hepatic carcinoma, but with improved OS in esophageal squamous cell carcinoma (ESCC). Furthermore, high IL-17A expression positively correlated with advanced TNM stage. In conclusion, High expression of intratumoral IL-17A leads to an unfavorable clinical outcome in majority of solid tumors, implicating IL-17A is a valuable biomarker for prognostic prediction of human solid malignances and targeting it may have a potential for effective treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.